CNSP

A.G.P. Role: A.G.P. is identified as the sole placement agent for a financial transaction.

CNS Pharmaceuticals Update: CNS Pharmaceuticals reports significant financial changes, with an EPS of ($38.87) compared to last year's ($12,509.11), and anticipates a cash runway extending into Q1 2026.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq gaining 0.29% while the Dow fell slightly by 0.06%. Notable stock movements included Tenon Medical's shares surging 287% and Mural Oncology's shares dropping 58%.

Economic Indicators: Sales of new single-family homes rose by 1.8% in February, despite a previous decline, while home price indices showed slight increases year-over-year, indicating ongoing fluctuations in the housing market.

Clinical Trial Results: CNS Pharmaceuticals announced that its clinical trial for Berubicin, a treatment for recurrent or progressive Glioblastoma Multiforme, did not show statistically significant improvement in overall survival compared to Lomustine, but demonstrated a favorable safety profile with no cardiotoxicity.

Financial Position and Stock Performance: The company reported an increase in cash reserves to $14 million, sufficient to fund operations into 2026, while its stock price has dropped by nearly 60%.

StoneCo Ltd Earnings Report: StoneCo Ltd shares rose 8% in pre-market trading after reporting better-than-expected fourth-quarter earnings and sales results.

Stock Movements: Several stocks saw significant pre-market movements, with Leishen Energy gaining 90%, while FST Corp fell 23% following a previous surge.

Current Financial Position: CNS Pharmaceuticals has reported an increase in cash reserves to $14 million, which is projected to fund operations through 2026, including upcoming milestones.

Nasdaq Listing Commitment: The CEO emphasized the importance of maintaining their Nasdaq listing, with expectations for significant developments by mid-2025 that will enhance the company's standing.

Airbnb Financial Results: Airbnb's shares surged 13.9% in pre-market trading after reporting fourth-quarter revenue of $2.5 billion, exceeding analyst expectations and marking a 12% year-over-year increase driven by growth in nights stayed and average daily rates.

Stock Movements: Several stocks experienced significant pre-market movements, with Virpax Pharmaceuticals gaining 78.4% following positive study results, while others like PicoCELA and Mynaric saw substantial declines of 54.6% and 39%, respectively, due to negative news or performance.

CNS Pharmaceuticals Update: CNS Pharmaceuticals has completed enrollment in a pivotal clinical trial for Berubicin, a treatment for glioblastoma multiforme, with primary data analysis expected in early 2025. The company has also in-licensed TPI 287, which has received Orphan and Fast Track designations for brain cancer treatment.

Company Overview: CNS Pharmaceuticals is focused on developing innovative treatments for brain cancer, with Berubicin as its lead program and TPI 287 expanding its pipeline; the company's current market cap is $6.72M.

Tesla's Earnings Surge: Tesla, Inc. shares rose 10.8% in pre-market trading after reporting third-quarter earnings per share of 72 cents, exceeding the expected 58 cents.

Market Movements: Various stocks experienced significant pre-market fluctuations, with CCSC Technology rising 122% and SaverOne dropping 25.9%, reflecting a mix of gains and losses across the market.

U.S. Stock Market Performance: U.S. stocks declined significantly, with the S&P 500 dropping over 1%, while sectors like real estate saw gains and technology shares fell. Notable stock movements included La Rosa Holdings surging 165% due to revenue growth, while Alto Neuroscience plummeted 67% after disappointing trial results.

Global Economic Indicators: European markets mostly closed lower, with a slight increase in Eurozone consumer confidence, while Asian markets showed mixed results. In the U.S., mortgage applications and existing home sales both decreased, alongside a significant rise in crude oil inventories.

U.S. Stock Market Performance: U.S. stocks declined midweek, with the Nasdaq Composite dropping over 1%, while AT&T reported better-than-expected earnings despite a slight revenue decline.

Global Market Trends: European shares mostly fell, Asian markets showed mixed results, and U.S. mortgage applications decreased by 6.7%, indicating ongoing economic challenges.

Stock Performance: CNS Pharmaceuticals Inc shares surged by 86% to 29 cents after receiving a Nasdaq notice regarding non-compliance with the minimum bid price requirement of $1.00 per share.

Compliance Hearing: The company has requested a hearing scheduled for November 5 to address potential delisting, as it is ineligible for a compliance extension due to prior reverse stock splits.

U.S. Stock Market Performance: U.S. stocks opened lower with the Dow Jones dropping over 250 points, while Boeing reported a significant loss for Q3, missing revenue expectations and showing an expanded adjusted loss per share.

Global Market Trends: European shares mostly declined, Asian markets closed mixed, and U.S. mortgage applications fell by 6.7%, indicating a broader trend of market instability and economic challenges.

Stride, Inc. Financial Results: Stride, Inc. shares surged 24.3% in pre-market trading after reporting first-quarter earnings of 94 cents per share, significantly exceeding the analyst estimate of 20 cents, along with sales of $551.084 million surpassing expectations.

Stock Movements: Several stocks experienced notable pre-market movements, including CNS Pharmaceuticals rising 99.4%, DBV Technologies gaining 75.7%, and Alto Neuroscience dropping 61.4% following disappointing trial results.

CNS Pharmaceuticals Compliance: CNS Pharmaceuticals has received confirmation from Nasdaq that it has regained compliance with the equity requirement.

Offering Announcement: The company announced a registered direct offering and concurrent private placement, resulting in a 6% drop in stock price after pricing the offering at $1.37 million.

CNS Pharmaceuticals Presentation: CNS Pharmaceuticals, Inc. will have its CEO, John Climaco, present at the LIVE! with Webull Corporate Connect Virtual Biotech Investment Webinar on August 28, 2024, at 3:20 PM ET to discuss recent corporate events.

Company Overview: CNS Pharmaceuticals is focused on developing innovative treatments for brain and central nervous system cancers, with their lead drug candidate, Berubicin, being notable for its ability to cross the blood-brain barrier and target aggressive brain cancer types like glioblastoma multiforme.

CNS Pharmaceuticals Q2 2024 Results: CNS Pharmaceuticals reported a second quarter earnings per share of -$6.72 and did not generate any revenue for the period.

InvestorPlace Earnings Automation: InvestorPlace utilizes automated data from TradeSmith to quickly publish key financial figures, including earnings and revenue, without human intervention.

Berubicin Trial Update: CNS Pharmaceuticals has completed enrollment for its pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (GBM), with topline results expected in the first half of 2025. The FDA has granted Fast Track and Orphan Drug Designations for Berubicin to expedite its development.

TPI 287 In-Licensing: The company has strategically in-licensed TPI 287, which shows promise in treating recurrent GBM and other cancers, and plans to seek FDA guidance for advancing it into a potential registration study, aiming to initiate this study in 2025.

Palantir Technologies Performance: Palantir Technologies Inc. shares rose 9.6% in pre-market trading after reporting second-quarter revenue of $678.13 million, surpassing estimates, along with adjusted earnings of 9 cents per share.

Market Movements: Several stocks experienced significant pre-market trading changes, with Lytus Technologies and Lumen Technologies gaining 79.1% and 44.8%, respectively, while SunPower Corporation saw a decline of 24.6% following its Chapter 11 filing.

Kellanova Acquisition Interest: Kellanova shares surged 14.5% in pre-market trading amid reports that Mars is considering acquiring the company.

Stock Movements: Various stocks experienced significant pre-market trading changes, with MGO Global rising 38.4% and Aqua Metals plummeting 60%.